Young women’s autonomy and information needs in the schools-based HPV vaccination programme: a qualitative study

BMC Public Health
http://bmcpublichealth.biomedcentral.com/articles
(Accessed 14 Nov 2020)

 

Young women’s autonomy and information needs in the schools-based HPV vaccination programme: a qualitative study
Until 2019, the English schools-based human papillomavirus (HPV) vaccination programme was offered to young women (but not young men) aged 12 to 13 years to reduce HPV-related morbidity and mortality. The aim …
Authors: Harriet Fisher, Karen Evans, Jo Ferrie, Julie Yates, Marion Roderick and Suzanne Audrey
Citation: BMC Public Health 2020 20:1680
Content type: Research article
Published on: 10 November 2020

Willingness to use HIV prevention methods among vaccine efficacy trial participants in Soweto, South Africa: discretion is important

BMC Public Health
http://bmcpublichealth.biomedcentral.com/articles
(Accessed 14 Nov 2020)

 

Willingness to use HIV prevention methods among vaccine efficacy trial participants in Soweto, South Africa: discretion is important
Despite multiple available HIV prevention methods, the HIV epidemic continues to affect South Africa the most. We sought to understand willingness to use actual and hypothetical HIV prevention methods among pa…
Authors: Fatima Laher, Taibat Salami, Stefanie Hornschuh, Lerato M. Makhale, Mamakiri Khunwane, Michele P. Andrasik, Glenda E. Gray, Hong Van Tieu and Janan J. Dietrich
Citation: BMC Public Health 2020 20:1669
Content type: Research article
Published on: 7 November 2020

Original research: Does electronic consent improve the logistics and uptake of HPV vaccination in adolescent girls? A mixed-methods theory informed evaluation of a pilot intervention

BMJ Open
November 2020 – Volume 10 – 11
https://bmjopen.bmj.com/content/10/11

 

Original research
Original research: Does electronic consent improve the logistics and uptake of HPV vaccination in adolescent girls? A mixed-methods theory informed evaluation of a pilot intervention (3 November, 2020)
Tracey Chantler, Ellen Pringle, Sadie Bell, Rosie Cooper, Emily Edmundson, Heidi Nielsen, Sheila Roberts, Michael Edelstein, Sandra Mounier-Jack

Literature Review: Strategies for Addressing Language Barriers During Humanitarian Relief Operations

Disaster Medicine and Public Health Preparedness
Volume 14 – Issue 3 – June 2020
https://www.cambridge.org/core/journals/disaster-medicine-and-public-health-preparedness/latest-issue

 

Concepts in Disaster Medicine
Literature Review: Strategies for Addressing Language Barriers During Humanitarian Relief Operations
Carlo Rossi, Sylvain Grenier, Régis Vaillancourt
Published online by Cambridge University Press: 23 October 2019, pp. 343-351

Genomics in the era of COVID-19: ethical implications for clinical practice and public health

Genome Medicine
https://genomemedicine.biomedcentral.com/articles
[Accessed 14 Nov 2020]

 

Genomics in the era of COVID-19: ethical implications for clinical practice and public health
Genomic studies of patients with COVID-19, or exposed to it, are underway to delineate host factors associated with variability in susceptibility, infectivity, and disease severity. Here, we highlight the ethical implications—both potential benefits and harms—of genomics for clinical practice and public health in the era of COVID-19.
Authors: Gail Geller, Priya Duggal, Chloe L. Thio, Debra Mathews, Jeffrey P. Kahn, Lisa L. Maragakis and Brian T. Garibaldi
Citation: Genome Medicine 2020 12:95
Content type: Comment
Published on: 9 November 2020

The global governance of antimicrobial resistance: a cross-country study of alignment between the global action plan and national action plans

Globalization and Health
http://www.globalizationandhealth.com/
[Accessed 14 Nov 2020]

 

The global governance of antimicrobial resistance: a cross-country study of alignment between the global action plan and national action plans
Antimicrobial resistance (AMR) is a growing problem worldwide in need of global coordinated action. With the endorsement of the Global Action Plan (GAP) on AMR in 2015, the 194 member states of the World Health Organization committed to integrating the five objectives and corresponding actions of the GAP into national action plans (NAPs) on AMR. The article analyzes patterns of alignment between existing NAPs and the GAP, bringing to the fore new methodologies for exploring the relationship between globally driven health policies and activities at the national level, taking income, geography and governance factors into account.
Authors: Louise Munkholm and Olivier Rubin
Content type: Research
11 November 2020

Disability inclusion in humanitarian action

Humanitarian Exchange Magazine
Number 78, October 2020
https://odihpn.org/magazine/inclusion-of-persons-with-disabilities-in-humanitarian-action-what-now/

 

Disability inclusion in humanitarian action
by HPN October 2020
The theme of this edition of Humanitarian Exchange, co-edited with Sherin Alsheikh Ahmed from Islamic Relief Worldwide, is disability inclusion in humanitarian action. Persons with disabilities are not only disproportionately impacted by conflicts, disasters and other emergencies, but also face barriers to accessing humanitarian assistance. At the same time, global commitments and standards and the IASC Guidelines on the inclusion of persons with disabilities in humanitarian action all emphasise how persons with disabilities are also active agents of change. Disability and age-focused organisations have led on testing and demonstrating how inclusion can be done better. Yet despite this progress, challenges to effective inclusion remain.

As Kirstin Lange notes in the lead article, chief among these challenges is humanitarian agencies’ lack of engagement with organisations of persons with disabilities. Simione Bula, Elizabeth Morgan and Teresa Thomson look at disability inclusion in humanitarian response in the Pacific, and Kathy Al Jubeh and Alradi Abdalla argue for a ‘participation revolution’, building on learning from the gender movement. Tchaurea Fleury and Sulayman AbdulMumuni Ujah outline how the Bridge Article 11 training initiative is encouraging constructive exchange between humanitarian and disability actors. The lack of good, disaggregated data is highlighted by Sarah Collinson; Frances Hill, Jim Cranshaw and Carys Hughes emphasise the need for training resources in local languages and accessible formats; and Sophie Van Eetvelt and colleagues report on a review of the evidence on inclusion of people with disabilities and older people.

Rebecca Molyneux and co-authors analyse the findings of a review of a DFID programme in north-east Nigeria, while Carolin Funke highlights the importance of strategic partnerships between disability-focused organisations, drawing on her research in Cox’s Bazar. Sherin Alsheikh Ahmed describes Islamic Relief Worldwide’s approach to mainstreaming protection and inclusion, while Pauline Thivillier and Valentina Shafina outline IRC’s Client Responsive Programming. The edition ends with reflections by Mirela Turcanu and Yves Ngunzi Kahashi on CAFOD’s SADI approach.

Spotlight on global health research

International Health
Volume 12, Issue 6, November 2020
https://academic.oup.com/inthealth/issue/12/6

 

EDITORIAL
Spotlight on global health research
David S Lawrence, Margaret Gyapong
International Health, Volume 12, Issue 6, November 2020, Pages 507–508, https://doi.org/10.1093/inthealth/ihaa082
Extract
Global health research is a discipline in which it is highly possible to cause more harm than good. Universally, the conduct of ethical research is bound by international principles and guidelines and its design and implementation are interrogated by funders and institutional review boards. Research in resource-limited settings is no different in this respect but poses additional ethical considerations due to the nature that the research is conducted alongside or within poorly resourced healthcare systems. The aim of this special issue is to identify work that acknowledges this complexity but demonstrates best practice in the…

Ethical research in global health emergencies: making the case for a broader understanding of ‘research ethics’

International Health
Volume 12, Issue 6, November 2020
https://academic.oup.com/inthealth/issue/12/6

 

COMMENTARY
Ethical research in global health emergencies: making the case for a broader understanding of ‘research ethics’
Katharine S Wright
International Health, Volume 12, Issue 6, November 2020, Pages 515–517, https://doi.org/10.1093/inthealth/ihaa053
Abstract
The ethical challenges of global health research become particularly acute in emergency contexts, and are exacerbated by historic inequities and imbalances in power and influence. Drawing on the findings of an international working group established by the Nuffield Council on Bioethics, this article argues for the need to take a broader approach to ‘research ethics’ as traditionally understood, to include the role of ‘duty-bearers’ such as funders, governments, research institutions and journals. An ‘ethical compass’ of three core values (equal respect, fairness and helping reduce suffering) supports ethical reflection at the level of policy, as well as on the ground.

Decolonising global health: transnational research partnerships under the spotlight

International Health
Volume 12, Issue 6, November 2020
https://academic.oup.com/inthealth/issue/12/6

 

ORIGINAL ARTICLES
Decolonising global health: transnational research partnerships under the spotlight
David S Lawrence, Lioba A Hirsch
International Health, Volume 12, Issue 6, November 2020, Pages 518–523, https://doi.org/10.1093/inthealth/ihaa073
Abstract
There are increasing calls to decolonise aspects of science, and global health is no exception. The decolonising global health movement acknowledges that global health research perpetuates existing power imbalances and aims to identify concrete ways in which global health teaching and research can overcome its colonial past and present. Using the context of clinical trials implemented through transnational research partnerships (TRPs) as a case study, this narrative review brings together perspectives from clinical research and social science to lay out specific ways in which TRPs build on and perpetuate colonial power relations. We will explore three core components of TRPs: participant experience, expertise and infrastructure, and authorship. By combining a critical perspective with recently published literature we will recommend specific ways in which TRPs can be decolonised. We conclude by discussing decolonising global health as a potential practice and object of research. By doing this we intend to frame the decolonising global health movement as one that is accessible to everyone and within which we can all play an active role.

Participant compensation in global health research: a case study

International Health
Volume 12, Issue 6, November 2020
https://academic.oup.com/inthealth/issue/12/6

 

Participant compensation in global health research: a case study
Compensation for research participants can be provided for reasons including reimbursement of costs; compensation for time lost, discomfort or inconvenience; or expression of appreciation for participation. This compensation involves numerous ethical complexities, at times entailing competing risks. In the context of transnational research, often incorporating contexts of economic inequality, power differentials and post-colonialism, these issues extend into wider questions of ethical research conduct.
Sepeedeh Saleh, Henry Sambakunsi, Deborah Nyirenda, Moses Kumwenda, Kevin Mortimer …
International Health, Volume 12, Issue 6, November 2020, Pages 524–532, https://doi.org/10.1093/inthealth/ihaa064

Towards a fair and transparent research participant compensation and reimbursement framework in Vietnam

International Health
Volume 12, Issue 6, November 2020
https://academic.oup.com/inthealth/issue/12/6

 

Towards a fair and transparent research participant compensation and reimbursement framework in Vietnam
Providing compensation for participants in clinical research is well established and while international guidelines exist, defining a context-specific and fair compensation for participants in low-resource settings is challenging due to ethical concerns and the lack of practical, national compensation and reimbursement frameworks.
Lucy J Sansom, Trang Pham Nguyen Minh, Iona E Hill, Quyen Nguyen Than Ha, Thuan Dang Trong …
International Health, Volume 12, Issue 6, November 2020, Pages 533–540, https://doi.org/10.1093/inthealth/ihaa066

Participant understanding of informed consent in a multidisease community-based health screening and biobank platform in rural South Africa

International Health
Volume 12, Issue 6, November 2020
https://academic.oup.com/inthealth/issue/12/6

 

Participant understanding of informed consent in a multidisease community-based health screening and biobank platform in rural South Africa
In low- and middle-income settings, obtaining informed consent for biobanking may be complicated by socio-economic vulnerability and context-specific power dynamics. We explored participants experiences and perceptions of the research objectives in a community-based multidisease screening and biospecimen collection platform in rural KwaZulu-Natal, South Africa.
Nothando Ngwenya, Manono Luthuli, Resign Gunda, Ntombizonke A Gumede, Oluwafemi Adeagbo …
International Health, Volume 12, Issue 6, November 2020, Pages 560–566, https://doi.org/10.1093/inthealth/ihaa072

Preprint Servers’ Policies, Submission Requirements, and Transparency in Reporting and Research Integrity Recommendations

JAMA
November 10, 2020, Vol 324, No. 18, Pages 1805-1916
https://jamanetwork.com/journals/jama/currentissue

 

Research Letter
Preprint Servers’ Policies, Submission Requirements, and Transparency in Reporting and Research Integrity Recommendations
Mario Malički, MD, MA, PhD; Ana Jerončić, MSc, PhD; Gerben ter Riet, MD, PhD; et al.
JAMA. 2020;324(18):1901-1903. doi:10.1001/jama.2020.17195
This study describes the policies, submission requirements, and transparency in reporting and research integrity recommendations of academic preprint servers.

Submissions and Downloads of Preprints in the First Year of medRxiv

JAMA
November 10, 2020, Vol 324, No. 18, Pages 1805-1916
https://jamanetwork.com/journals/jama/currentissue

 

Submissions and Downloads of Preprints in the First Year of medRxiv
Harlan M. Krumholz, MD, SM; Theodora Bloom, PhD; Richard Sever, PhD; et al.
JAMA. 2020;324(18):1903-1905. doi:10.1001/jama.2020.17529
This study describes submissions, postings, abstract views, downloads, comments, and withdrawals on the medRxiv preprint server from June 2019 to June 2020 and compares submissions and postings before and after COVID-19.

Sensible Medicine—Balancing Intervention and Inaction During the COVID-19 Pandemic

JAMA
November 10, 2020, Vol 324, No. 18, Pages 1805-1916
https://jamanetwork.com/journals/jama/currentissue

 

Viewpoint
Sensible Medicine—Balancing Intervention and Inaction During the COVID-19 Pandemic
Christopher W. Seymour, MD, MSc; Erin K. McCreary, PharmD; Jacob Stegenga, PhD
free access has active quiz has audio
JAMA. 2020;324(18):1827-1828. doi:10.1001/jama.2020.20271
This Viewpoint discusses the tensions between rapid adoption of interventions for coronavirus disease 2019 (COVID-19) before adequate evidence justifies their use and therapeutic nihilism, and argues for sensible medicine between the 2, which favors usual care, disfavors unnecessary interventions, but embraces rapid scientific evaluation with clinical translation of options proven effective.

Reflections on the Importance of Community-Partnered Research Strategies for Health Equity in the Era of COVID-19

Journal of Health Care for the Poor and Underserved (JHCPU)
Volume 31, Number 4, November 2020
https://muse.jhu.edu/issue/42831

 

Table of Contents
Reflections on the Importance of Community-Partnered Research Strategies for Health Equity in the Era of COVID-19
Savanna L. Carson, Cynthia Gonzalez, Sylvia Lopez, D’Ann Morris, Norma Mtume, Aziza Lucas-Wright, Stefanie D. Vassar, Keith C. Norris, Arleen F. Brown
pp. 1515-1519

High time to prioritize rabies prevention—a new paradigm

Journal of Travel Medicine
Volume 27, Issue 7, October 2020
https://academic.oup.com/jtm/issue/27/7

 

Editorial
High time to prioritize rabies prevention—a new paradigm
Robert Steffen, MD, Davidson H Hamer, MD
Journal of Travel Medicine, Volume 27, Issue 7, October 2020, taaa173, https://doi.org/10.1093/jtm/taaa173
Almost 500 patients consulted a GeoSentinel clinic annually for post-exposure prophylaxis after a potential rabies exposure as compared to approximately 20 for hepatitis A and 40 for typhoid fever. Travellers’ response after potential rabies exposure is alarmingly inadequate. Thus, rabies pre-exposure prophylaxis should now become the #1 travel vaccine intervention.

A risk scoring system to identify travellers who qualify for pre-exposure rabies vaccination

Journal of Travel Medicine
Volume 27, Issue 7, October 2020
https://academic.oup.com/jtm/issue/27/7

 

A risk scoring system to identify travellers who qualify for pre-exposure rabies vaccination
Mieke Croughs, MD PhD, Patrick Soentjens, MD PhD
Journal of Travel Medicine, Volume 27, Issue 7, October 2020, taaa168, https://doi.org/10.1093/jtm/taaa168
We want to introduce a free online scoring system to identify high risk travellers who qualify for pre-travel rabies vaccination. The system uses evidence based risk predictors and the probable availability of HRIG at the destination.

The Riyadh Declaration: the role of digital health in fighting pandemics

The Lancet
Nov 14, 2020 Volume 396 Number 10262 p1535-1606, e83-e88
https://www.thelancet.com/journals/lancet/issue/current

 

Comment
The Riyadh Declaration: the role of digital health in fighting pandemics
Bandar Al Knawy, et al.
The COVID-19 pandemic has exposed weaknesses in health and care systems and global public health responses, some of which can be addressed through data and digital science. The Riyadh Declaration on Digital Health was formulated during the Riyadh Global Digital Health Summit, Aug 11–12, 2020, a landmark forum that highlighted the importance of digital technology, data, and innovation for resilient global health and care systems.

Our panel of 13 experts articulated seven key priorities and nine recommendations (below) for data and digital health that need to be adopted by the global health community to address the challenges of the COVID-19 pandemic and future pandemics.

Recommendations from the Riyadh Global Digital Health Summit
1 Implement data-driven and evidence-based protocols for clear and effective communication with common messaging to build citizens’ trust
2 Work with global stakeholders to confront propagation of misinformation or disinformation through social media platforms and mass media
3 Implement a standard global minimum dataset for public health data reporting and a data governance structure tailored to communicable diseases
4 Ensure countries prioritise digital health, particularly, improving digital health infrastructure and reaching digital maturity
5 Enable health and care organisations by providing the necessary technology to collect high-quality data in a timely way and promote sharing to create health intelligence
6 Cultivate a health and care workforce with the knowledge, skills, and training in data and digital technologies required to address current and future public health challenges
7 Ensure surveillance systems combine an effective public health response with respect for ethical and privacy principles
8 Develop digital personal tools and services to support comprehensive health programmes (in disease prevention, testing, management, and vaccination) globally
9 Maintain, continue to fund, and innovate surveillance systems as a core component of the connected global health system for rapid preparedness and optimal global responses

The first priority is for the health and care sectors to adopt applied health intelligence (HI). HI represents a systematic approach and comprehensive methodology applied to the collection, linkage, analysis, and use of appropriate health data. HI is used for the surveillance, monitoring, and improvement of population and patient outcomes, and for assessing the efficiency and effectiveness of policies, programmes, and services.1

The second priority relates to interoperable digital technology and for this technology to be scaled up and sustainable. Digital health tools and services require a secure, trusted flow of data with scalability and interoperability support. The advent of commercial cloud computing services and distributed systems has paved the way for scalable, cost-effective service provision.

The third priority is to support the adoption of artificial intelligence (AI). Use of AI in health systems demands rapid access to various data types, often not possible in health-care settings with slow data flows.2 AI also requires vast amounts of high-quality data to achieve acceptable accuracy and validity. Health-care organisations and systems need to provide the necessary technology to collect and share high-quality data.

Effective communication about public health crises and risk is the fourth priority. Such communication requires an understanding of risk and the timely dissemination of information; seamless digital integration of case reports and deaths; and effective data visualisation tools such as map-based dashboards.3Effective communication to change knowledge, attitudes, and behaviours mandates the systematic exploration of diverse digital channels and the innovative design of digital tools for citizen engagement.4

The fifth priority concerns health data governance, quality, policy, regulation, and use. Passively generated digital location data from mobile phones and internet services provide crucial information about human mobility and interactions.5

However, ethics and privacy are essential and must be adhered to when using these ubiquitous data. Projections about disease epidemics require human mobility and interaction data that are aggregated in time and space to reconstruct population-level behaviour.6

The sixth priority relates to the quality and effectiveness of digital technology for improved patient and population outcomes. Digital technologies offer many opportunities to improve the quality and effectiveness of care, patient outcomes, and population health.7

Digital health systems should be designed and implemented to maximise data quality and access for clinicians and patients and these systems should be interoperable.
The seventh priority is research and innovation. Investing in, conducting, publishing, and promoting transparent research are foundational to digital health advances that leverage data, analytics, and AI.8

It can take an average of 17 years to translate a major medical research discovery to widespread delivery.9

The competitive, commercial culture of technology revolves around disruptive innovation, iterative discoveries, and the delivery of new technologies over months, not years. To translate life-saving innovations in digital health into widespread applications, collaboration across the best of research and innovation in health and technology is essential.

The Riyadh Declaration on Digital Health is a call to action to create the infrastructure needed to share effective digital health evidence-based practices and high-quality, real-time data locally and globally to provide actionable information to more health systems and countries. Digital and data technologies have a role in promoting the coordinated development of shared global public health policies and resilient health and care systems. These technologies can support health systems and governments to perform better in future pandemics and other global health challenges. We call on state actors to ensure that digital technology and innovation become the cornerstone of a resilient global health and care system that places individual and population health at the forefront of our future endeavours.

SARS-CoV-2 immunity: review and applications to phase 3 vaccine candidates

The Lancet
Nov 14, 2020 Volume 396 Number 10262 p1535-1606, e83-e88
https://www.thelancet.com/journals/lancet/issue/current

 

Review
SARS-CoV-2 immunity: review and applications to phase 3 vaccine candidates
Gregory A Poland, Inna G Ovsyannikova, Richard B Kennedy
Summary
Understanding immune responses to severe acute respiratory syndrome coronavirus 2 is crucial to understanding disease pathogenesis and the usefulness of bridge therapies, such as hyperimmune globulin and convalescent human plasma, and to developing vaccines, antivirals, and monoclonal antibodies. A mere 11 months ago, the canvas we call COVID-19 was blank. Scientists around the world have worked collaboratively to fill in this blank canvas. In this Review, we discuss what is currently known about human humoral and cellular immune responses to severe acute respiratory syndrome coronavirus 2 and relate this knowledge to the COVID-19 vaccines currently in phase 3 clinical trials.

US president-elect Joe Biden must quickly restore science to government

Nature
Volume 587 Issue 7833, 12 November 2020
http://www.nature.com/nature/current_issue.html

 

Editorial | 09 November 2020
US president-elect Joe Biden must quickly restore science to government
The election of Biden and Kamala Harris is a win for facts, research and empathy. Each of these must be deployed to fight the pandemic, combat misinformation, mitigate climate change and rebuild the United States’ global relationships.

A comparative genomics multitool for scientific discovery and conservation

Nature
Volume 587 Issue 7833, 12 November 2020
http://www.nature.com/nature/current_issue.html

 

Analysis | 11 November 2020
A comparative genomics multitool for scientific discovery and conservation
A whole-genome alignment of 240 phylogenetically diverse species of eutherian mammal—including 131 previously uncharacterized species—from the Zoonomia Project provides data that support biological discovery, medical research and conservation.
Diane P. Genereux, Aitor Serres[…] & Elinor K. Karlsson

The Covid-19 Vaccine-Development Multiverse

New England Journal of Medicine
November 12, 2020 Vol. 383 No. 20
http://www.nejm.org/toc/nejm/medical-journal

 

Editorial
The Covid-19 Vaccine-Development Multiverse
Penny M. Heaton, M.D.
Leaving in its wake more than 12 million infections, over 550,000 deaths, and an economic toll in the trillions of dollars to date,1 the SARS-CoV-2 pandemic has devastated the most vulnerable in our society — adults 65 years of age or older, persons with underlying conditions, and the economically deprived.2 A vaccine is urgently needed to prevent Covid-19 and thereby stem complications and deaths resulting from transmission of the disease.

Jackson et al. now report in the Journal preliminary findings from a phase 1 trial to evaluate the safety and immunogenicity of an mRNA SARS-CoV-2 vaccine.3 Phase 1 involves 45 healthy adults, 18 to 55 years of age, who were assigned to receive the candidate vaccine at one of three dose levels (25 μg, 100 μg, or 250 μg) given as two vaccinations 28 days apart. These preliminary findings represent the first of three reports of data from a phase 1 study of this candidate vaccine; a second report including similar data from adults older than 55 years of age and a final report summarizing the safety and durability of immunity for both study cohorts are also planned.

The speed with which this vaccine has been developed is remarkable — from publication of the first SARS-CoV-2 sequences through phase 1 in 6 months, as compared with a typical timeline of 3 to 9 years (Figure 1). The rapid pace of development of vaccines against Covid-19 is enabled by several factors: prior knowledge of the role of the spike protein in coronavirus pathogenesis and evidence that neutralizing antibody against the spike protein is important for immunity4,5; the evolution of nucleic acid vaccine technology platforms that allow creation of vaccines and prompt manufacture of thousands of doses once a genetic sequence is known6; and development activities that can be conducted in parallel, rather than sequentially, without increasing risks for study participants.

The safety and immunogenicity data in this preliminary report are promising, and they support continued development of this vaccine. However, we must bear in mind the complexity of vaccine development and the work still to be done before Covid-19 vaccines are widely available.

Many phase 3 studies fail because of incorrect identification of the dose that best balances safety and efficacy.7 The dosing regimen for this mRNA vaccine is still under study. The 250-μg dose did not appear to be associated with markedly higher antibody titers than the 100-μg dose, but it was associated with a higher proportion of severe systemic adverse events. As the investigators indicate, it is prudent to evaluate doses of 100 μg and lower to define the regimen that provides the most appropriate benefit–risk profile for this vaccine. Another special dosing consideration in this case is age: the immune functions that decline with age and that are likely to be responsible for the greater risk of severe Covid-19 in older adults may also lead to poor vaccine responses. Will a high-dose Covid-19 vaccine be needed for effective protection of older adults, as observed with influenza vaccines?8

The clinical significance of SARS-CoV-2 binding and neutralizing antibody titers and their ability to predict efficacy will need to be confirmed. These measures are currently being used to guide dose selection before being verified; they are the best tools available and are supported by findings in nonhuman primates.9 Confirmation of the correlation between antibody titers and protection against Covid-19 will be possible only in a large clinical efficacy study. In the meantime, the validity of the assays for measuring antibody will also need to be documented. These assays are notoriously variable because they use live virus or protein expression in cell culture with a readout that relies on an in vitro biologic reaction (i.e., serum antibodies binding or killing viral antigen). Optimization of the performance characteristics of these assays will be invaluable in streamlining further development and supporting bridging across varied populations and manufacturing processes.

The authors indicate that a planned phase 3 trial of this mRNA SARS-CoV-2 vaccine is imminent; the trial will require thousands of subjects in order to confirm the safety of the vaccine and to show statistically robust efficacy in preventing Covid-19. The operational complexity inherent in a large study is compounded by the undulations of the pandemic; efficacy can be determined only if there is a match between the location of vaccinated participants and pandemic hot spots. Uncertainty regarding the expected efficacy profile also drives complexity; the profiles observed for other viral vaccines suggest that efficacy against severe Covid-19 may be higher than efficacy against mild disease. Careful selection of primary end points and event-driven study designs with the possibility of sample size reestimation should be considered.

Accelerating the development of Covid-19 vaccine candidates beyond phase 1 depends on continued parallel tracking of activities and fulsome resources. The world has now witnessed the compression of 6 years of work into 6 months. Can the vaccine multiverse do it again, leading to a reality of a safe, efficacious Covid-19 vaccine for the most vulnerable in the next 6?

Figure 1. Traditional Vaccine Development Pathway.

Covid-19 Vaccine Trials and Incarcerated People — The Ethics of Inclusion

New England Journal of Medicine
November 12, 2020 Vol. 383 No. 20
http://www.nejm.org/toc/nejm/medical-journal

 

Perspective
Covid-19 Vaccine Trials and Incarcerated People — The Ethics of Inclusion
Camila Strassle, B.A., et al
… There are three arguments for enrolling incarcerated people in vaccine trials. First, it would offer them early access to a potentially efficacious vaccine. Second, it would provide them with a choice to participate in medical research that will be offered to nonincarcerated people. Third, it could shorten the amount of time needed to study vaccine efficacy, if transmission rates continue to be higher in correctional facilities than elsewhere.
Research involving incarcerated populations is ethically, legally, and logistically complex…

An mRNA Vaccine against SARS-CoV-2 — Preliminary Report

New England Journal of Medicine
November 12, 2020 Vol. 383 No. 20
http://www.nejm.org/toc/nejm/medical-journal

 

Original Article
An mRNA Vaccine against SARS-CoV-2 — Preliminary Report
Lisa A. Jackson, M.D., M.P.H., et al.
We conducted a first-in-human phase 1 clinical trial in healthy adults to evaluate the safety and immunogenicity of mRNA-1273. Here we report interim results of the trial.
Abstract
Conclusions
The mRNA-1273 vaccine induced anti–SARS-CoV-2 immune responses in all participants, and no trial-limiting safety concerns were identified. These findings support further development of this vaccine. (Funded by the National Institute of Allergy and Infectious Diseases and others; mRNA-1273 ClinicalTrials.gov number, NCT04283461. opens in new tab).
This article was published on July 14, 2020, and updated on August 25, 2020, at NEJM.org.

Decision-making on maternal pertussis vaccination among women in a vaccine-hesitant religious group: Stages and needs

PLoS One
http://www.plosone.org/

 

Research Article
Decision-making on maternal pertussis vaccination among women in a vaccine-hesitant religious group: Stages and needs
Anne C. de Munter, Wilhelmina L. M. Ruijs, Robert A. C. Ruiter, Dagmar J. J. van Nimwegen, Anke J. M. Oerlemans, Rijk van Ginkel, Marlies E. J. L. Hulscher, Jeannine L. A. Hautvast
Research Article | published 12 Nov 2020 PLOS ONE
https://doi.org/10.1371/journal.pone.0242261

Human Papillomavirus (HPV) and the quadrivalent HPV Vaccine among Brazilian adolescents and parents: Factors associated with and divergences in knowledge and acceptance

PLoS One
http://www.plosone.org/

 

Human Papillomavirus (HPV) and the quadrivalent HPV Vaccine among Brazilian adolescents and parents: Factors associated with and divergences in knowledge and acceptance
Jéssica Menezes Gomes, Beatriz Machado Silva, Edige Felipe de Sousa Santos, Patricia Jane Kelly, Annielson de Souza Costa, Albertina Duarte Takiuti, Luiz Carlos de Abreu, José Maria Soares Júnior, Edmund Chada Baracat, Isabel Cristina Esposito Sorpreso
Research Article | published 12 Nov 2020 PLOS ONE

Repurposing therapeutics for COVID-19: Rapid prediction of commercially available drugs through machine learning and docking

PLoS One
http://www.plosone.org/

 

Repurposing therapeutics for COVID-19: Rapid prediction of commercially available drugs through machine learning and docking
Sovesh Mohapatra, Prathul Nath, Manisha Chatterjee, Neeladrisingha Das, Deepjyoti Kalita, Partha Roy, Soumitra Satapathi
Research Article | published 12 Nov 2020 PLOS ONE
https://doi.org/10.1371/journal.pone.0241543

Using a Respectful Approach to Child-centred Healthcare (ReACH) in a paediatric clinical trial: A feasibility study

PLoS One
http://www.plosone.org/

 

Using a Respectful Approach to Child-centred Healthcare (ReACH) in a paediatric clinical trial: A feasibility study
Analise Nicholl, Kate Evelegh, Kane Evan Deering, Kate Russell, David Lawrence, Philippa Lyons-Wall, Therese Anne O’Sullivan
Research Article | published 09 Nov 2020 PLOS ONE
https://doi.org/10.1371/journal.pone.0241764

Harnessing early life immunity to develop a pediatric HIV vaccine that can protect through adolescence

PLoS Pathogens
http://journals.plos.org/plospathogens/
[Accessed 14 Nov 2020]

 

Pearls
Harnessing early life immunity to develop a pediatric HIV vaccine that can protect through adolescence
Ria Goswami, Stella J. Berendam, Shuk Hang Li, Ashley N. Nelson, Kristina De Paris, Koen K. A. Van Rompay, Sallie R. Permar, Genevieve G. Fouda
| published 12 Nov 2020 PLOS Pathogens
https://doi.org/10.1371/journal.ppat.1008983

Equity, intercultural approaches and access to information on traditional, complementary and integrative medicines in the Americas

Revista Panamericana de Salud Pública/Pan American Journal of Public Health (RPSP/PAJPH)
https://www.paho.org/journal/en

13 Nov 2020
Equity, intercultural approaches and access to information on traditional, complementary and integrative medicines in the Americas
Current topic | Spanish |
Access to information and intercultural approaches in the field of health are essential for the elimination of inequities in health access and care. Intercultural models such as traditional, complementary and integrative medicine (TCIM) are an important part of health care in most countries and often contribute to expanding access to primary health care. Despite legal recognition and policies to integrate TCIM into health systems, their contribution to health, well-being, and people-centered care to achieve universal health is still underestimated. This article presents the progress (2017-2020) achieved by the Virtual Health Library specialized in the TCIM (VHL TCIM Americas), an initiative created as a tool to reduce the gaps in the production and access to validated information on TCIM. Through collaborative network work, the VHL TCIM Americas contributes to the democratization of health, access to verified scientific data, visibility of non-conventional knowledge, strengthening of research capacities, and exchange of experiences for informed decision-making.

Intentions to Seek Information About the Influenza Vaccine: The Role of Informational Subjective Norms, Anticipated and Experienced Affect, and Information Insufficiency Among Vaccinated and Unvaccinated People

Risk Analysis
Volume 40, Issue 10 Pages: 1887-2111 October 2020
https://onlinelibrary.wiley.com/toc/15396924/current

 

Original Research Articles
Intentions to Seek Information About the Influenza Vaccine: The Role of Informational Subjective Norms, Anticipated and Experienced Affect, and Information Insufficiency Among Vaccinated and Unvaccinated People
Hang Lu, , Kenneth Winneg, Kathleen Hall Jamieson, Dolores Albarracín
Pages: 2040-2056
First Published: 19 February 2020

What’s next for COVID-19 apps? Governance and oversight

Science
13 November 2020 Vol 370, Issue 6518
http://www.sciencemag.org/current.dtl

 

Policy Forum
What’s next for COVID-19 apps? Governance and oversight
By Alessandro Blasimme, Effy Vayena
Science13 Nov 2020 : 760-762 Full Access
Adaptive governance can help earn social license
Summary
Many governments have seen digital health technologies as a promising tool to address coronavirus disease 2019 (COVID-19), particularly digital contact tracing (DCT) apps such as Bluetooth-based exposure notification apps that trace proximity to other devices (1) and GPS-based apps that collect geolocation data. But deploying these systems is fraught with challenges, and most national DCT apps have not yet had the expected rate of uptake. This can be attributed to a number of uncertainties regarding general awareness of DCT apps, privacy risks, and the actual effectiveness of DCT, as well as public attitudes toward a potentially pervasive form of digital surveillance. DCT thus appears to face a typical social control dilemma. On one hand, pending widespread uptake, assessing DCT effectiveness is extremely difficult; on the other hand, until DCT effectiveness is proven, its widespread use at a population scale is hard to justify. Recognizing that technological uptake is an open-ended process reliant upon social learning and the piecemeal creation of public trust, we suggest that policy-makers set up mechanisms to test effectiveness, oversee the use of DCT apps, monitor public attitudes, and adapt technological design to socially perceived risks and expectations.

Brighton Collaboration Viral Vector Vaccines Safety Working Group (V3SWG) standardized template for collection of key information for benefit-risk assessment of live-attenuated viral vaccines

Vaccine
Volume 38, Issue 49 Pages 7697-7876 (17 November 2020)
https://www.sciencedirect.com/journal/vaccine/vol/38/issue/49

 

Review article Open access
Brighton Collaboration Viral Vector Vaccines Safety Working Group (V3SWG) standardized template for collection of key information for benefit-risk assessment of live-attenuated viral vaccines
Marc Gurwith, Richard C. Condit, Jean-Louis Excler, James S. Robertson, … Sonali Kochhar
Pages 7702-7707

The Brighton Collaboration standardized template for collection of key information for benefit-risk assessment of viral vector vaccines

Vaccine
Volume 38, Issue 49 Pages 7697-7876 (17 November 2020)
https://www.sciencedirect.com/journal/vaccine/vol/38/issue/49

 

Review article Open access
The Brighton Collaboration standardized template for collection of key information for benefit-risk assessment of viral vector vaccines
Richard C Condit, Denny Kim, James S. Robertson, Jean-Louis Excler, … Sonali Kochhar
Pages 7708-7715

Lessons learned in the implementation of supplementary immunization activity (SIA) field guidelines for injectable vaccines – Experiences from Tanzania

Vaccine
Volume 38, Issue 49 Pages 7697-7876 (17 November 2020)
https://www.sciencedirect.com/journal/vaccine/vol/38/issue/49

 

Research article Abstract only
Lessons learned in the implementation of supplementary immunization activity (SIA) field guidelines for injectable vaccines – Experiences from Tanzania
Nassor Mohamed, Daudi Simba, Alex Mphuru, Dafrossa Lyimo, Furaha Kyesi
Pages 7741-7746

Parents’ and guardians’ views on the acceptability of a future COVID-19 vaccine: A multi-methods study in England

Vaccine
Volume 38, Issue 49 Pages 7697-7876 (17 November 2020)
https://www.sciencedirect.com/journal/vaccine/vol/38/issue/49

 

Research article Open access
Parents’ and guardians’ views on the acceptability of a future COVID-19 vaccine: A multi-methods study in England
Sadie Bell, Richard Clarke, Sandra Mounier-Jack, Jemma L. Walker, Pauline Paterson
Pages 7789-7798

Influenza vaccination: A qualitative study of practice level barriers from medical practitioners caring for children with special risk medical conditions

Vaccine
Volume 38, Issue 49 Pages 7697-7876 (17 November 2020)
https://www.sciencedirect.com/journal/vaccine/vol/38/issue/49

 

Research article Full text access
Influenza vaccination: A qualitative study of practice level barriers from medical practitioners caring for children with special risk medical conditions
Jane L Tuckerman, Jessica Kaufman, Margie Danchin, Helen S Marshall
Pages 7806-7814

Global assessment of national mandatory vaccination policies and consequences of non-compliance

Vaccine
Volume 38, Issue 49 Pages 7697-7876 (17 November 2020)
https://www.sciencedirect.com/journal/vaccine/vol/38/issue/49

 

Research article Open access
Global assessment of national mandatory vaccination policies and consequences of non-compliance
Katie Gravagna, Andy Becker, Robert Valeris-Chacin, Inari Mohammed, … Nicole E. Basta
Pages 7865-7873
Highlights
:: Over 100 countries have a nationwide mandatory vaccination policy requiring one or more vaccines.
:: Of those, 62 countries (59%) also impose one or more penalties against individuals who do not comply.
:: Educational and financial penalties are the most common types of penalties; severity varies.
:: Most educational penalties deny school enrollment until vaccination requirements are met.
Abstract
Background
Declining vaccination coverage and increasing hesitancy is a worldwide concern. Many countries have implemented mandatory vaccination policies to promote vaccination. However, mandatory vaccination policies differ significantly by country. Beyond case studies, no comprehensive study has compared these policies or the penalties for non-compliance on a global scale.
Methods
We conducted extensive keyword, policy, and literature searches to identify mandatory national vaccination policies globally and develop a comprehensive database. A mandatory national vaccination policy was defined as a policy from a national authority that requires individuals to receive at least one vaccination based on age or to access a service. Two reviewers independently evaluated evidence for a mandate and whether non-compliance penalties were incorporated. We categorized penalties into four types, based on the nature of the penalty. These penalties impact an individual’s financial, parental rights, educational (i.e., child’s school entry and access), and liberty status. We rated the severity within each category.
Results
Of 193 countries investigated, 54% (n = 105) had evidence of a nationwide mandate as of December 2018. The frequency, types, and severity of penalties varied widely across all regions. We found that 59% (n = 62) of countries with national mandates defined at least one penalty for non-compliance with a vaccine mandate. Among those, educational penalties (i.e., limiting a child’s entry or ongoing access to school) were the most common (69%; n = 43), with most countries with educational penalties refusing school enrollment until vaccination requirements are met (81%; n = 35).
Conclusion
We undertook a comprehensive assessment of national mandatory vaccination policies and identified a diversity of penalties in place to promote compliance. Our results highlight the need to critically evaluate the implementation of non-compliance penalties in order to determine their effectiveness and to define best practices for sustaining high vaccination uptake worldwide.

Media/Policy Watch

Media/Policy Watch
This watch section is intended to alert readers to substantive news, analysis and opinion from the general media and selected think tanks and similar organizations on vaccines, immunization, global public health and related themes. Media Watch is not intended to be exhaustive, but indicative of themes and issues CVEP is actively tracking. This section will grow from an initial base of newspapers, magazines and blog sources, and is segregated from Journal Watch above which scans the peer-reviewed journal ecology.
We acknowledge the Western/Northern bias in this initial selection of titles and invite suggestions for expanded coverage. We are conservative in our outlook in adding news sources which largely report on primary content we are already covering above. Many electronic media sources have tiered, fee-based subscription models for access. We will provide full-text where content is published without restriction, but most publications require registration and some subscription level.

 

The Atlantic
http://www.theatlantic.com/magazine/
Accessed 14 Nov 2020
Ideas
For a Vaccine to Save Lives, Society Has to Make Some Decisions
In distributing a coronavirus vaccine, the U.S. needs to learn from past mistakes.
6:00 AM ET
Thomas J. Bollyky, Director of the Global Health Program at the Council on Foreign Relations

 

BBC
http://www.bbc.co.uk/
Accessed 14 Nov 2020
[No new, unique, relevant content]

 

The Economist
http://www.economist.com/
Accessed 14 Nov 2020
Leaders Nov 14th 2020 edition
Suddenly, hope…The promise of the new covid-19 vaccine is immense
But don’t underestimate the challenge of getting people vaccinated

 

Financial Times
https://www.ft.com/
Accessed 14 Nov 2020
US politics & policy
US vaccine tsar calls on White House to allow contact with Biden
November 13, 2020

 

Forbes
http://www.forbes.com/
Accessed 14 Nov 2020
Breaking  |
5 hours ago
Here’s Why Trump And Cuomo Are Feuding Over A Coronavirus Vaccine
Trump threatened to withhold a vaccine from New York after Cuomo repeatedly declared Trump’s distribution plan and safety measures inadequate.
By Andrew Solender Forbes Staff

 

Foreign Affairs
http://www.foreignaffairs.com/
Accessed 14 Nov 2020
[No new, unique, relevant content]

 

Foreign Policy
http://foreignpolicy.com/
Accessed 14 Nov 2020
Vaccine Inequality Fuels Suspicion and Division
The world can’t repeat the mistakes of polio, tuberculosis, and measles.
Argument | Oussama Mezoui November 12, 2020, 12:52 PM

 

Kremlin Spin Doctors are Leading Russia’s Vaccine Development
With Sputnik V, the country is conflating good headlines with good health.
Argument | Chris Miller November 12, 2020, 12:23 PM

 

As Vaccine Hopes Grow, Poorer Countries Are Last in Line
A vaccine candidate closely linked with Operation Warp Speed is expected to produce preliminary results similar to the blockbuster Pfizer findings.
Morning Brief | Colm Quinn November 12, 2020, 5:10 AM

 

The Guardian
http://www.guardiannews.com/
Accessed 14 Nov 2020
[No new, unique, relevant content]

 

New Yorker
http://www.newyorker.com/
Accessed 14 Nov 2020
Politics and More Podcast
A Nobel Laureate on the Politics of Fighting the Coronavirus
Dr. Harold E. Varmus, a former director of the National Institutes of Health and winner of a Nobel Prize in Medicine, on combating COVID-19 during the Biden Administration.
By Dorothy Wickenden November 12, 2020

 

New York Times
http://www.nytimes.com/
Accessed 14 Nov 2020
Sunday Review
This Coronavirus Surge Does Not Have to Be So Horrific
America is entering a difficult period. But the outcome is not foregone.
By The Editorial Board

Health
Missing From State Plans to Distribute the Coronavirus Vaccine: Money to Do It
The government has sent billions to drug companies to develop a coronavirus shot but a tiny fraction of that to localities for training, record-keeping and other costs for vaccinating citizens.
By Abby Goodnough and Sheila Kaplan

Health
As the Pandemic Surges, C.D.C. Issues Increasingly Assertive Advice
Agency scientists often contradict the Trump administration now, but critics urge a more public stance.
By Apoorva Mandavilli

 

Washington Post
https://www.washingtonpost.com/
World · Nov 12, 2020
Analysis
Vaccines have never been distributed equally. A coronavirus vaccine would be no different, history suggests
Ruby Mellen ·

Think Tanks et al

Think Tanks et al

Brookings
http://www.brookings.edu/
Accessed 14 Nov 2020
[No new relevant content]
 
 
Center for Global Development [to 14 Nov 2020]
http://www.cgdev.org/page/press-center
November 12, 2020
Beyond the Rhetoric of Equity: Will the Frontline Healthcare Workers Who Serve the Poor Be Prioritized for the COVID Vaccine?
Healthcare providers, particularly in low- and middle-income countries, are a diverse, fragmented, and loosely regulated population. Will the COVID vaccine plans prioritize them?
Asif Saleh, Maria Khan and Richard A. Cash
 
 
Chatham House [to 14 Nov 2020]
https://www.chathamhouse.org/
Event
Members Event The Virus, the Vaccine and Violence
23 November 2020 — 4:00PM TO 5:15PM
This webinar assesses the potential for conflict-sensitive approaches to COVID-19 with a focus on vaccines.

 

CSIS
https://www.csis.org/
Accessed 14 Nov 2020
[No new relevant content]

 

Council on Foreign Relations
http://www.cfr.org/
Accessed 14 Nov 2020
[No new relevant content]

 

Kaiser Family Foundation
https://www.kff.org/search/?post_type=press-release
Accessed 14 Nov 2020
November 11, 2020 News Release
New Brief Examines COVID-19 Risks and Impacts for Health Care Workers by Race and Ethnicity
New coronavirus cases in the United States have hit daily records multiple times in the past week and hospitalizations are rising in several areas of the country. Health care workers face some of the greatest risk of exposure to the coronavirus and a new KFF brief examines the composition of…